Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
Biochemical Pharmacology|January 26, 2010
Emerging immunotherapies targeting CD30 in Hodgkin's lymphomaHans-Peter GerberCancer Research|February 12, 2005
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studiesHans-Peter Gerber, Napoleone FerraraJournal of Molecular Medicine (Berlin, Germany)|January 25, 2003
The role of VEGF in normal and neoplastic hematopoiesisHans-Peter Gerber, Napoleone FerraraFrontiers in Oncology|November 7, 2022
TCR mimic compounds for pHLA targeting with high potency modalities in oncologyHans-Peter Gerber, Leonard G PrestaNature Medicine|June 5, 2003
The biology of VEGF and its receptorsNapoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouterMolecular Immunology|October 12, 2014
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignanciesBoris Shor, Hans-Peter Gerber, Puja SapraMabs|July 6, 2023
Therapeutic index improvement of antibody-drug conjugatesHans-Peter Gerber, Sanjeev Gangwar, Alison BettsMolecular Cancer Therapeutics|October 27, 2016
Mechanisms of Resistance to Antibody-Drug ConjugatesFrank Loganzo, Matthew Sung, Hans-Peter GerberBiochemical Pharmacology|August 4, 2012
Advances in bispecific biotherapeutics for the treatment of cancerChad May, Puja Sapra, Hans-Peter GerberRecent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|December 25, 2009
Targeting inflammatory cells to improve anti-VEGF therapies in oncologyHans-Peter Gerber, Ezogelin Olazoglu, Iqbal S GrewalPageof 8